CB-103 Plus NSAI In Luminal Advanced Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer
Interventions: DRUG: CB-103
Sponsor: MedSIR
Collaborators: Cellestia Biotech AG